William Tester

Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233

Raymond H. Mak, Daniel Hunt, William U. Shipley et al. · Journal of Clinical Oncology · 2014 · 438 citations · Full text

Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of rtog protocol 85-12

William Tester, Arthur T. Porter, Sucha O. Asbell et al. · International Journal of Radiation Oncology*Biology*Physics · 1993 · 281 citations

Urology, Surgical Oncology, Possible Organ Preservation +7

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.

William Tester, Richard Caplan, John Heaney et al. · Journal of Clinical Oncology · 1996 · 276 citations

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

Veda N. Giri, Karen E. Knudsen, William Kevin Kelly et al. · Journal of Clinical Oncology · 2020 · 273 citations · Full text

Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma

G Lemma, Ju-Whei Lee, Seena C. Aisner et al. · Journal of Clinical Oncology · 2011 · 234 citations · Full text